Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Data From ESMO 2023 Further Define Treatment Paradigm in Advanced Melanoma

January 23rd 2024

Oncologists reviewed data from clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care.

Rate of End-of-Life Immunotherapy Is on the Rise in Advanced Melanoma, NSCLC, RCC

January 15th 2024

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.

ctDNA Patterns May Predict Outcomes Achieved With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma

January 15th 2024

Jeffrey S. Weber, MD, PhD, expands on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma.

Neoadjuvant Cemiplimab Prolongs Survival in Stage II to IV CSCC

January 12th 2024

Neil D. Gross, MD, FACS, shares how neoadjuvant cemiplimab followed by surgery improved EFS in patients with stage II-IV cutaneous squamous cell carcinoma.

Dr Possik on the Importance of Diversity and Equity in Melanoma Research

January 11th 2024

Patricia A. Possik, PhD, discusses the importance of efforts to improve diversity, equity, and inclusion in melanoma research.

Lifileucel Demonstrates Long-Term Efficacy and Survival Benefit in Advanced, Pretreated Melanoma

January 5th 2024

Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors.

Oncolytic Adenovirus TILT-123 Combined With TIL Therapy Is Safe in Metastatic Melanoma

January 5th 2024

Intravenous and intratumoral treatment with TILT-123 was found to be safe and feasible, with no dose-limiting toxicities when given alone or in combination with tumor infiltrating lymphocyte therapy in patients with advanced, metastatic melanoma.

The Future of Metastatic and Unresectable Melanoma Treatment

January 4th 2024

The panel concludes their discussion with a call for continued research and collaboration, emphasizing the need for more understanding of targeted therapies, monitoring tools like ctDNA, and ongoing development in the field of BRAF mutant melanoma treatment.

Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases

January 4th 2024

Doctors discuss the effectiveness of different treatment combinations for patients with BRAF-mutated metastatic melanoma and brain metastases, highlighting that consideration of patient preferences is essential in making treatment decisions.

Treatment Approaches For Patients With BRAF-Mutated Melanoma and Symptomatic Brain Metastases

December 21st 2023

Experts discuss treatment of patients with BRAF-mutated melanoma and symptomatic brain metastases, detailing radiation therapy, corticosteroid use, and the choice between BRAF/MEK inhibitor therapy and immunotherapy.

Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases

December 21st 2023

For patients with BRAF-mutated melanoma with asymptomatic brain metastases, immunotherapy, particularly the combination of ipilimumab and nivolumab, is the preferred treatment option due to its effectiveness and durability, as supported by the seven-year follow-up data from the CHECKMATE 204 trial.

SD-101 With Immune Checkpoint Inhibition Generates Positive Results in Uveal Melanoma Liver Metastasis

December 18th 2023

Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of Tregs, M-MDSCs, and M2 macrophages in liver metastases in patients with uveal melanoma.

FDA Issues Complete Response Letter to Cosibelimab for Cutaneous Squamous Cell Carcinoma

December 18th 2023

The FDA has issued a complete response letter to the biologic license application seeking the approval of cosibelimab for use in patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation.

OBX-115 Elicits Responses in Advanced or Metastatic Melanoma

December 16th 2023

The tumor-infiltrating lymphocyte cell therapy OBX-115 produced responses with no dose-limiting toxicities in heavily pretreated patients with advanced or metastatic melanoma whose who had progressed on anti–PD-1 and anti–CTLA-4 therapy with disease that was primary-resistant to immune checkpoint inhibitor therapy.

FDA Grants Fast Track Status to Naporafenib Plus Trametinib for Advanced NRAS-Mutated Melanoma

December 15th 2023

The FDA has granted fast track designation to naporafenib plus trametinib for use as a potential therapeutic option in adult patients with unresectable or metastatic melanoma with an NRAS mutation who progressed on or are intolerant to a PD-1/PD-L1–based regimen.

RP1 Plus Cemiplimab Misses Response End Points in Locally Advanced or Metastatic CSCC

December 14th 2023

The combination of RP1 and cemiplimab provided a numerical, but not statistically significant, improvement in response rates vs cemiplimab alone in patients with locally advanced or metastatic cutaneous squamous cell carcinoma, missing the primary end points of the phase 2 CERPASS trial.

Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma

December 14th 2023

Panelists discuss the potential benefits of rechallenging patients with BRAF-mutated metastatic melanoma with BRAF/MEK inhibitors after a break from treatment, especially for those who initially responded well, and emphasizing the success of this approach in some cases, while highlighting the importance of monitoring and utilizing ctDNA tracking for more informed decision-making.

Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial

December 14th 2023

The 7-year follow-up data for encorafenib/binimetinib showing that around 21% of patients remained progression-free supports BRAF/MEK inhibition as a later treatment option after immunotherapy failure, but doctors are reluctant to stop BRAF/MEK inhibitors given lack of data, even in those patients doing well long-term on the medications with minimal toxicity.

Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma

December 7th 2023

The panel explains which BRAF/MEK inhibitor combination therapy they each tend to turn to when treating a patient with BRAF-mutated metastatic melanoma.

Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma

December 7th 2023

Key opinion leaders explain that clinicians should warn patients with BRAF-mutated metastatic melanoma starting BRAF/MEK inhibitor therapy about short-term toxicities like fever, chills, and rash that can differ greatly from immunotherapy toxicities.